| Market Capitalization (Millions $) |
13,214 |
| Shares
Outstanding (Millions) |
118 |
| Employees |
730 |
| Revenues (TTM) (Millions $) |
831 |
| Net Income (TTM) (Millions $) |
54 |
| Cash Flow (TTM) (Millions $) |
6 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Corcept Therapeutics Inc. is an American pharmaceutical company that is focused on the discovery, development, and commercialization of drugs that target cortisol to treat severe metabolic, oncologic, and psychiatric disorders.
The company was founded in 1998 by Dr. Joseph Belanoff and is headquartered in Menlo Park, California. Its primary drug is mifepristone, which is an oral medication that is used to treat Cushing's Syndrome, a rare hormonal disorder that is caused by the overproduction of cortisol. Mifepristone has been FDA-approved since 2012 and is marketed under the brand name Korlym.
In addition to Korlym, Corcept has a pipeline of proprietary drugs, including CORT125134, CORT118335, and CORT125281 that are currently in various stages of clinical development. These drugs target several different indications, such as triple-negative breast cancer, ovarian cancer, and Cushing's Syndrome.
Corcept has a seasoned management team that has extensive experience in the biopharmaceutical industry. The company is led by Dr. Joseph Belanoff, who serves as its Chief Executive Officer and President. He co-founded the company and has a long history of working in the field of psychiatry and endocrinology. The company's Chief Medical Officer is Dr. Paris Panayiotopoulos, who has over 25 years of experience in clinical development and is responsible for overseeing the clinical development of Corcept's drug candidates.
Corcept has a strong intellectual property portfolio, with numerous patents and patent applications that cover its proprietary drugs and technologies. The company also has collaborations with several academic institutions and research organizations to advance its drug development programs.
In 2020, Corcept reported total revenues of $421 million and had a net income of $230.4 million. The company has a market capitalization of approximately $6 billion as of August 2021 and is publicly traded on the NASDAQ stock exchange under the ticker symbol CORT.
Company Address: 101 Redwood Shores Parkway Redwood City 94065 CA
Company Phone Number: 327-3270 Stock Exchange / Ticker: NASDAQ CORT
|
6.37% 
145.81 %